Genenta Science (NASDAQ:GNTA) Stock Price Down 1.3% – Time to Sell?

Genenta Science S.p.A. (NASDAQ:GNTA) dropped 1.3% during mid-day trading on Friday . The company traded as low as $3.51 and last traded at $3.76. Approximately 22,483 shares traded hands during trading, an increase of 43% from the average daily volume of 15,753 shares. The stock had previously closed at $3.81.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Genenta Science in a report on Wednesday, October 2nd.

Genenta Science Stock Performance

The stock’s fifty day moving average is $4.88 and its 200-day moving average is $4.55.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. purchased a new stake in Genenta Science S.p.A. (NASDAQ:GNTA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned approximately 1.10% of Genenta Science as of its most recent filing with the Securities and Exchange Commission (SEC). 15.13% of the stock is owned by institutional investors and hedge funds.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.